
Graybug Vision GRAY
Graybug Vision EV - Enterprise Value | GRAY
Annual EV - Enterprise Value Graybug Vision
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.71 M | -2.55 M | 472 K | 11.3 M | 11.9 M | 60 M | 12.3 M | 5.79 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 60 M | -2.55 M | 13.5 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Johnson & Johnson
JNJ
|
98 B | $ 274.89 | 0.95 % | $ 662 B | ||
|
Titan Pharmaceuticals
TTNP
|
-2.35 M | - | -3.76 % | $ 3.47 M | ||
|
Lineage Cell Therapeutics
LCTX
|
450 M | $ 1.02 | 3.75 % | $ 235 M | ||
|
BioVie
BIVI
|
-12.6 M | $ 1.33 | 9.92 % | $ 1.96 M | ||
|
Longeveron
LGVN
|
16.9 B | $ 1.82 | 6.43 % | $ 32 B | ||
|
Allena Pharmaceuticals
ALNA
|
11.9 M | - | 3.16 % | $ 1.9 M | ||
|
TCR2 Therapeutics
TCRR
|
92.6 M | - | - | $ 58.1 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
4.14 B | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Mustang Bio
MBIO
|
-5.03 M | $ 0.39 | 0.15 % | $ 1.91 M | ||
|
TFF Pharmaceuticals
TFFP
|
7.83 M | - | -60.05 % | $ 125 K | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-721 K | $ 1.63 | 1.87 % | $ 2.68 M | ||
|
Mesoblast Limited
MESO
|
12.6 B | $ 14.26 | 1.13 % | $ 17.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
5.68 B | $ 93.81 | 0.28 % | $ 4.71 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
143 M | - | -15.15 % | $ 60.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
111 M | - | - | $ 521 M | ||
|
Codexis
CDXS
|
157 M | $ 1.09 | 6.37 % | $ 95 M | ||
|
MannKind Corporation
MNKD
|
1.76 B | $ 3.91 | 4.0 % | $ 1.2 B | ||
|
MediciNova
MNOV
|
42.4 M | $ 1.44 | -0.69 % | $ 70.7 M | ||
|
Axcella Health
AXLA
|
22.6 M | - | -16.42 % | $ 249 M | ||
|
Merck & Co.
MRK
|
296 B | $ 146.81 | -0.07 % | $ 367 B | ||
|
Dynavax Technologies Corporation
DVAX
|
2.02 B | - | - | $ 2.02 B | ||
|
Tyme Technologies
TYME
|
-5.81 M | - | 8.07 % | $ 54 M | ||
|
Curis
CRIS
|
18.9 M | $ 0.88 | 3.67 % | $ 11.6 M | ||
|
Cyclerion Therapeutics
CYCN
|
10.1 M | $ 34.99 | 3.77 % | $ 147 M | ||
|
Завод ДИОД
DIOD
|
3.14 B | - | - | - | ||
|
CorMedix
CRMD
|
276 M | $ 5.31 | 1.43 % | $ 383 K | ||
|
Novartis AG
NVS
|
369 B | $ 162.64 | 0.44 % | $ 315 B | ||
|
CRISPR Therapeutics AG
CRSP
|
4.38 B | $ 50.09 | 3.15 % | $ 4.5 B | ||
|
PDS Biotechnology Corporation
PDSB
|
19.6 M | $ 1.22 | 4.27 % | $ 56.6 M | ||
|
Pfizer
PFE
|
275 B | $ 29.39 | -0.22 % | $ 167 B | ||
|
Pharming Group N.V.
PHAR
|
11.8 B | $ 12.32 | 0.16 % | $ 8.49 B | ||
|
Orgenesis
ORGS
|
38.8 M | - | -33.86 % | $ 61.2 M | ||
|
Cytokinetics, Incorporated
CYTK
|
1.97 B | $ 53.74 | -3.26 % | $ 6.45 M | ||
|
Фармсинтез
LIFE
|
59.3 B | - | - | - | ||
|
Prothena Corporation plc
PRTA
|
-10.4 M | $ 7.93 | 0.51 % | $ 427 M | ||
|
Codiak BioSciences
CDAK
|
284 M | - | -55.98 % | $ 2.15 M | ||
|
DBV Technologies S.A.
DBVT
|
2.69 B | $ 10.54 | 7.55 % | $ 1.47 B | ||
|
Rocket Pharmaceuticals
RCKT
|
283 M | $ 2.38 | -2.05 % | $ 264 M | ||
|
Regeneron Pharmaceuticals
REGN
|
87.4 B | $ 904.69 | 0.2 % | $ 94.6 B | ||
|
Replimune Group
REPL
|
997 M | $ 21.67 | 8.24 % | $ 2.01 B | ||
|
DiaMedica Therapeutics
DMAC
|
296 M | $ 9.47 | 4.76 % | $ 445 M | ||
|
Royalty Pharma plc
RPRX
|
28.2 B | $ 67.31 | -0.39 % | $ 28.9 B | ||
|
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
6.5 B | $ 111.51 | 6.18 % | $ 7.25 B | ||
|
Puma Biotechnology
PBYI
|
434 M | $ 8.28 | -15.25 % | $ 414 M | ||
|
SIGA Technologies
SIGA
|
270 M | $ 3.12 | 4.55 % | $ 223 M | ||
|
Sage Therapeutics
SAGE
|
436 M | - | - | $ 527 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
250 M | - | - | $ 1.62 B | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
199 M | $ 61.62 | -2.21 % | $ 172 M | ||
|
SELLAS Life Sciences Group
SLS
|
503 M | $ 8.41 | 6.73 % | $ 917 M |